Perspectives on the interlinked nature of systemic sclerosis and reflux disease

References

• Khanna D, Distler JHW, Sandner P, et al. Emerging strategies for treatment of systemic sclerosis. J Scleroderma Relat Disord. 2016;1(2):186–193.
   Web of Science ®Google Scholar
• Roberts CG, Hummers LK, Ravich WJ, et al. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006;55(12):1697–1703.
   PubMed Web of Science ®Google Scholar
• Thoua NM, Bunce C, Brough G, et al. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology (Oxford). 2010;49(9):1770–1775.
   PubMed Web of Science ®Google Scholar
• Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67(7):1351–1362.
   PubMed Web of Science ®Google Scholar
• Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: A study using pH-impedance monitoring. Am J Respir Crit Care Med. 2009;179(5):408–413.
   PubMed Web of Science ®Google Scholar
• Gyawali CP, Roman S, Bredenoord AJ, et al. Classification of esophageal motor findings in gastro-esophageal reflux disease: conclusions from an international consensus group. Neurogastroenterol Motil. 2017;29(12):e13104.
   Web of Science ®Google Scholar
• Vaezi MF, Richter JE. Duodenogastro-oesophageal reflux. Baillieres Best Pract Res Clin Gastroenterol. 2000;14(5):719–729.
   PubMed Web of Science ®Google Scholar
• Clarke JO, Pandolfino JE., et al. Upper gastrointestinal tract: manifestations of systemic sclerosis. In: Varga J, Denton CP, Wigley FM, editors. Scleroderma: from pathogenesis to comprehensive management. Cham: Springer International Publishing; 2017. p. 427–441.
   Google Scholar
• Kirby DF, Chatterjee S. Evaluation and management of gastrointestinal manifestations in scleroderma. Curr Opin Rheumatol. 2014;26(6):621–629.
   PubMed Web of Science ®Google Scholar
• Kumar S, Singh J, Rattan S, et al. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. Aliment Pharmacol Ther. 2017;45(7):883–898.
   PubMed Web of Science ®Google Scholar
• Kumar S, Singh J, Kedika R, et al. Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G1052–G1060.
   PubMed Web of Science ®Google Scholar
• DeMeester TR, Smith CD. 25th anniversary state-of-the-art expert discussion with Tom R. DeMeester, MD, on GERD. J Laparoendosc Adv Surg Tech A. 2015;25(9):695–701.
   PubMed Web of Science ®Google Scholar
• DeMeester TR. Understanding GERD in the twenty-first century [Internet]. University of Wisconsin School of Medicine and Public Health - Department of Surgery; 2014 [cited 2018 Jan 10]. Madison, WI. Available from: https://cme.surgery.wisc.edu/watch/165
   Google Scholar
• Dunbar KB, Agoston AT, Odze RD, et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA. 2016;315(19):2104–2112.
   PubMed Web of Science ®Google Scholar
• Souza RF, Bayeh L, Spechler SJ, et al. A new paradigm for gerd pathogenesis. Not acid injury, but cytokine-mediated inflammation driven by HIF-2alpha: A potential role for targeting HIF-2alpha to prevent and treat reflux esophagitis. Curr Opin Pharmacol. 2017;37:93–99.
   PubMed Web of Science ®Google Scholar
• Chandrasoma PT. GERD: A new understanding of pathology, pathophysiology, and treatment. 1st ed. London: Academic Press; 2017 Oct 26. English.
   Google Scholar
• Pearson JP, Parikh S, Orlando RC, et al. Review article: reflux and its consequences–the laryngeal, pulmonary and oesophageal manifestations. Conference held in conjunction with the 9th international symposium on human pepsin (ISHP) Kingston-upon-Hull, UK, 21-23 April 2010. Aliment Pharmacol Ther. 2011;33(Suppl 1):1–71.
   PubMedGoogle Scholar
• Keir GJ, Silver RM, Wells AU, et al. Clinical assessment of lung disease. In: Varga J, Denton CP, Wigley FM, editors. Scleroderma: from pathogenesis to comprehensive management. Cham: Springer International Publishing; 2017. p. 363–373.
   Google Scholar
• Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev. 2017;26(143):160027.
   PubMed Web of Science ®Google Scholar
• de Souza RB, Borges CT, Capelozzi VL, et al. Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis. Respiration. 2009;77(4):389–397.
   PubMed Web of Science ®Google Scholar
• Aldhahrani A, Powell J, Ladak S, et al. The potential role of bile acids in acquired laryngotracheal stenosis. Laryngoscope. 2018. DOI:10.1002/lary.27105.
   PubMed Web of Science ®Google Scholar
• Perng DW, Chang KT, Su KC, et al. Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: A relation to transforming growth factor-beta1 production and fibroblast proliferation. Chest. 2007;132(5):1548–1556.
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Kia L. Pepsin: A silent biomarker for reflux aspiration or an active player in extra-esophageal mucosal injury? Chest. 2015;148(2):300–301.
   PubMed Web of Science ®Google Scholar
• Lin C, Borensztajn K, Spek CA. Targeting coagulation factor receptors - protease-activated receptors in idiopathic pulmonary fibrosis. J Thromb Haemost. 2017;15(4):597–607.
   PubMed Web of Science ®Google Scholar
• Kimmel JN, Carlson DA, Hinchcliff M, et al. The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. Neurogastroenterol Motil. 2016;28(8):1157–1165.
   PubMed Web of Science ®Google Scholar
• Thonhofer R, Siegel C, Trummer M, et al. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int. 2012;32(1):165–168.
   PubMed Web of Science ®Google Scholar
• Lepri G, Guiducci S, Bellando-Randone S, et al. Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. Ann Rheum Dis. 2015;74(1):124–128.
   PubMed Web of Science ®Google Scholar
• Ahuja NK, Clarke JO. The role of impedance planimetry in the evaluation of esophageal disorders. Curr Gastroenterol Rep. 2017;19(2):7.
   PubMedGoogle Scholar
• Shaheen NJ, Falk GW, Iyer PG, et al. Acg clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50;quiz 51.
   Web of Science ®Google Scholar
• Wipff J, Coriat R, Masciocchi M, et al. Outcomes of Barrett’s oesophagus related to systemic sclerosis: A 3-year eular scleroderma trials and research prospective follow-up study. Rheumatology (Oxford). 2011;50(8):1440–1444.
   PubMed Web of Science ®Google Scholar
• Quante M, Graham TA, Jansen M. Insights into the pathophysiology of esophageal adenocarcinoma. Gastroenterology. 2018;154(2):406–420.
   PubMed Web of Science ®Google Scholar
• DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg. 2000;231(3):303–321.
   PubMed Web of Science ®Google Scholar
• Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): A randomised factorial trial. Lancet. 2018;392(10145):400–408.
   PubMed Web of Science ®Google Scholar
• Benjamin T, Zackria S, Lopez R, et al. Upper esophageal sphincter abnormalities and high-resolution esophageal manometry findings in patients with laryngopharyngeal reflux. Scand J Gastroenterol. 2017;52(8):816–821.
   PubMed Web of Science ®Google Scholar
• Houghton LA, Lee AS, Badri H, et al. Respiratory disease and the oesophagus: reflux, reflexes and microaspiration. Nat Rev Gastroenterol Hepatol. 2016;13(8):445–460.
   PubMed Web of Science ®Google Scholar
• Iudici M, Moroncini G, Cipriani P, et al. Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? Autoimmun Rev. 2015;14(7):575–578.
   PubMed Web of Science ®Google Scholar
• Ghebre YT, Raghu G. Idiopathic pulmonary fibrosis: novel concepts of proton pump inhibitors as antifibrotic drugs. Am J Respir Crit Care Med. 2016;193(12):1345–1352.
   PubMed Web of Science ®Google Scholar
• Savarino E, Carbone R, Marabotto E, et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J. 2013;42(5):1322–1331.
   PubMed Web of Science ®Google Scholar
• Khanna D, Gladue H, Channick R, et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum. 2013;65(12):3194–3201.
   PubMedGoogle Scholar
• Yan J, Strong AT, Sharma G, et al. Surgical management of gastroesophageal reflux disease in patients with systemic sclerosis. Surg Endosc. 2018;32(9):3855–3860.
   PubMed Web of Science ®Google Scholar
• Vaezi MF, Pandolfino JE, Vela MF, et al. AGA white paper: optimal strategies to define and diagnose gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2017;15(8):1162–1172.
   PubMed Web of Science ®Google Scholar
• Hungin APS, Molloy-Bland M, Scarpignato C. Revisiting Montreal: new insights into symptoms and their causes, and implications for the future of GERD. Am J Gastroenterol. 2018. DOI:10.1038/s41395-018-0287-1
   PubMedGoogle Scholar
• Chandrasoma P, DeMeester TR. A new pathologic assessment of gastroesophageal reflux disease: the squamo-oxyntic gap. Adv Exp Med Biol. 2016;908:41–78.
   PubMed Web of Science ®Google Scholar
• Shreiner AB, Khanna D. Chapter 13 - gastrointestinal involvement in systemic sclerosis. In: Atzeni F, Masala IF, Aletaha D, et al., editors. Handbook of systemic autoimmune diseases. Vol. 13. Amsterdam: Elsevier; 2017. p. 243–261.
   Google Scholar
• Hansi N, Thoua N, Carulli M, et al. Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin Exp Rheumatol. 2014;32(6 Suppl 86):S-214–S-221.
   PubMed Web of Science ®Google Scholar
• Crowell MD, Umar SB, Griffing WL, et al. Esophageal motor abnormalities in patients with scleroderma: heterogeneity, risk factors, and effects on quality of life. Clin Gastroenterol Hepatol. 2017;15(2):207–213 e201.
   PubMed Web of Science ®Google Scholar
• Kwiatek MA, Pandolfino JE, Kahrilas PJ. 3D-high resolution manometry of the esophagogastric junction. Neurogastroenterol Motil. 2011;23(11):e461–e469.
   PubMed Web of Science ®Google Scholar
• Richardson C, Agrawal R, Lee J, et al. Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study. Semin Arthritis Rheum. 2016;46(1):109–114.
   PubMed Web of Science ®Google Scholar
• Salaffi F, Di Carlo M, Carotti M, et al. Relationship between interstitial lung disease and oesophageal dilatation on chest high-resolution computed tomography in patients with systemic sclerosis: A cross-sectional study. Radiol Med. 2018;123(9):655–663.
   PubMed Web of Science ®Google Scholar
• Fynne L, Liao D, Aksglaede K, et al. Esophagogastric junction in systemic sclerosis: A study with the functional lumen imaging probe. Neurogastroenterol Motil. 2017;29(8):e13073.
   Web of Science ®Google Scholar
• Kim MP, Meisenbach LM, Chan EY. Tailored fundoplication with endoluminal functional lumen imaging probe allows for successful minimally invasive hiatal hernia repair. Surg Laparosc Endosc Percutan Tech. 2018;28(3):178–182.
   PubMed Web of Science ®Google Scholar
• Yadlapati R, Hungness ES, Pandolfino JE. Complications of antireflux surgery. Am J Gastroenterol. 2018;113(8):1137–1147.
   PubMed Web of Science ®Google Scholar
• Arif T, Masood Q, Singh J, et al. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: A prospective comparative hospital based study. BMC Gastroenterol. 2015;15:24.
   PubMed Web of Science ®Google Scholar
• Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil. 2017;29(10):1–15.
   PubMed Web of Science ®Google Scholar
• Raja J, Ng CT, Sujau I, et al. High-resolution oesophageal manometry and 24-hour impedance-pH study in systemic sclerosis patients: association with clinical features, symptoms and severity. Clin Exp Rheumatol. 2016;34(Suppl 5):115–121.
   PubMed Web of Science ®Google Scholar
• Carlo-Stella N, Belloli L, Barbera R, et al. Gastroesophageal reflux and lung disease in systemic sclerosis. Am J Respir Crit Care Med. 2009;179(12):1167;author reply 1167–1168.
   PubMedGoogle Scholar
• Uslu Kizilkan N, Bozkurt MF, Saltik Temizel IN, et al. Comparison of multichannel intraluminal impedance-pH monitoring and reflux scintigraphy in pediatric patients with suspected gastroesophageal reflux. World J Gastroenterol. 2016;22(43):9595–9603.
   PubMed Web of Science ®Google Scholar
• RefluxMD Inc. Gerd diet [Internet]. RefluxMD, Inc.; 2018 [cited 2018 Jun 11]. San Diego, CA. Available from: https://www.refluxmd.com/gerd-diet/
   Google Scholar
• Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):302–318.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339.
   PubMed Web of Science ®Google Scholar
• Oldfield IEC, Parekh PJ, Johnson DA. Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis. Expert Rev Gastroenterol Hepatol. 2016;10(10):1083–1089.
   PubMed Web of Science ®Google Scholar
• Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;16(6):800–808 e807.
   PubMed Web of Science ®Google Scholar
• Jurgens S, Meyer F, Spechler SJ, et al. The role of bile acids in the neoplastic progression of Barrett’s esophagus - a short representative overview. Z Gastroenterol. 2012;50(9):1028–1034.
   PubMed Web of Science ®Google Scholar
• Pardon NA, Vicario M, Vanheel H, et al. A weakly acidic solution containing deoxycholic acid induces esophageal epithelial apoptosis and impairs integrity in an in vivo perfusion rabbit model. Am J Physiol Gastrointest Liver Physiol. 2016;310(7):G487–G496.
   PubMed Web of Science ®Google Scholar
• Souza RF. From reflux esophagitis to esophageal adenocarcinoma. Dig Dis. 2016;34(5):483–490.
   PubMed Web of Science ®Google Scholar
• Hegyi P, Maleth J, Walters JR, et al. Guts and gall: bile acids in regulation of intestinal epithelial function in health and disease. Physiol Rev. 2018;98(4):1983–2023.
   PubMed Web of Science ®Google Scholar
• Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018;53:172–177.
   PubMed Web of Science ®Google Scholar
• Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: A systematic review and meta-analysis. Gut. 2014;63(8):1229–1237.
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: A nested case control study in the UK. Gut. 2006;55(11):1538–1544.
   PubMed Web of Science ®Google Scholar
• Nason KS, Wichienkuer PP, Awais O, et al. Gastroesophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis. Arch Surg. 2011;146(7):851–858.
   PubMedGoogle Scholar
• Hvid-Jensen F, Pedersen L, Funch-Jensen P, et al. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: A nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014;39(9):984–991.
   PubMed Web of Science ®Google Scholar
• Hu Q, Sun TT, Hong J, et al. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: A systematic review and meta-analysis. PLoS One. 2017;12(1):e0169691.
   PubMed Web of Science ®Google Scholar
• McCabe ME, Dilly CK. New causes for the old problem of bile reflux gastritis. Clin Gastroenterol Hepatol. 2018;16(9):1389–1392.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Nocon M, Vieth M, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care–the ProGERD study. Aliment Pharmacol Ther. 2012;35(1):154–164.
   PubMed Web of Science ®Google Scholar
• Johnston N, Ondrey F, Rosen R, et al. Airway reflux. Ann N Y Acad Sci. 2016;1381(1):5–13.
   PubMedGoogle Scholar
• Savarino V, Pace F, Scarpignato C, et al. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45(5):631–642.
   PubMed Web of Science ®Google Scholar
• Wang YK, Hsu WH, Wang SS, et al. Current pharmacological management of gastroesophageal reflux disease. Gastroenterol Res Pract. 2013;2013:983653.
   PubMed Web of Science ®Google Scholar
• Maret-Ouda J, Konings P, Lagergren J, et al. Antireflux surgery and risk of esophageal adenocarcinoma: A systematic review and meta-analysis. Ann Surg. 2016;263(2):251–257.
   PubMed Web of Science ®Google Scholar
• Patti MG, Vela MF, Odell DD, et al. The intersection of GERD, aspiration, and lung transplantation. J Laparoendosc Adv Surg Tech A. 2016;26(7):501–505.
   PubMed Web of Science ®Google Scholar
• Raghu G, Pellegrini CA, Yow E, et al. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): A multicentre, randomised, controlled phase 2 trial. Lancet Respir Med. 2018;6(9):707–714.
   PubMed Web of Science ®Google Scholar
• Shah RJ, Boin F. Lung transplantation in patients with systemic sclerosis. Curr Rheumatol Rep. 2017;19(5):23.
   PubMed Web of Science ®Google Scholar
• Goldberg MB, Abbas AE, Smith MS, et al. Minimally invasive fundoplication is safe and effective in patients with severe esophageal hypomotility. Innovations (Phila). 2016;11(6):396–399.
   PubMedGoogle Scholar
• Telem DA, Wright AS, Shah PC, et al. SAGES technology and value assessment committee (TAVAC) safety and effectiveness analysis: LINX(R) reflux management system. Surg Endosc. 2017;31(10):3811–3826.
   PubMed Web of Science ®Google Scholar
• Ganz RA, Edmundowicz SA, Taiganides PA, et al. Long-term outcomes of patients receiving a magnetic sphincter augmentation device for gastroesophageal reflux. Clin Gastroenterol Hepatol. 2016;14(5):671–677.
   PubMed Web of Science ®Google Scholar
• Torax Medical, Inc. Todd Berg presentation - Torax medical spring meeting May 2011 in Frankfurt [Internet]. YouTube; 2011 [cited 2018 Jun 11]. Available from: https://youtu.be/YUoAPIgxxzE
   Google Scholar
• Schwameis K, Nikolic M, Morales Castellano DG, et al. Results of magnetic sphincter augmentation for gastroesophageal reflux disease. World J Surg. 2018;42(10):3263–3269.
   PubMed Web of Science ®Google Scholar
• Sriratanaviriyakul N, Kivler C, Vidovszky TJ, et al. LINX(R), a novel treatment for patients with refractory asthma complicated by gastroesophageal reflux disease: A case report. J Med Case Rep. 2016;10(1):124.
   PubMedGoogle Scholar
• Furnari M, Savarino V, de Bortoli N, et al. Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. Autoimmun Rev. 2016;15(12):1208–1209.
   PubMed Web of Science ®Google Scholar
• Alicuben ET, Tatum JM, Bildzukewicz N, et al. Regression of intestinal metaplasia following magnetic sphincter augmentation device placement. Surg Endosc. 2018. [Epub ahead of print]. doi: 10.1007/s00464-018-6367-x
   Web of Science ®Google Scholar
• Kowal-Bielecka O, Chwiesko-Minarowska S, Bernatowicz PL, et al. The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: A multicentre European Scleroderma Trials and Research group (EUSTAR) study. Rheumatology (Oxford). 2017;56(5):844–852.
   PubMed Web of Science ®Google Scholar
• Terao C, Kawaguchi T, Dieude P, et al. Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. Ann Rheum Dis. 2017;76(6):1150–1158.
   PubMed Web of Science ®Google Scholar
• Lundell L, Bell M, Ruth M. Systematic review: laparoscopic fundoplication for gastroesophageal reflux disease in partial responders to proton pump inhibitors. World J Gastroenterol. 2014;20(3):804–813.
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang Z, Ni Z, et al. A meta-analysis and systematic review of the efficacy of twice daily PPIs versus once daily for treatment of gastroesophageal reflux disease. Gastroenterol Res Pract. 2017;2017:9865963.
   PubMed Web of Science ®Google Scholar
• Aiolfi A, Asti E, Bernardi D, et al. Early results of magnetic sphincter augmentation versus fundoplication for gastroesophageal reflux disease: systematic review and meta-analysis. Int J Surg. 2018;52:82–88.
   PubMed Web of Science ®Google Scholar
• Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev. 2015;11:CD003243. DOI:10.1002/14651858.CD003243.pub3
   PubMed Web of Science ®Google Scholar
• Richter J, Kumar A, Lipka S, et al. Efficacy of laparoscopic Nissen fundoplication vs transoral incisionless fundoplication or proton pump inhibitors in patients with gastroesophageal reflux disease: A systematic review and network meta-analysis. Gastroenterology. 2018;154(5):1298–1308.
   PubMed Web of Science ®Google Scholar
• Skubleny D, Switzer NJ, Dang J, et al. LINX(R) magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: A systematic review and meta-analysis. Surg Endosc. 2017;31(8):3078–3084.
   PubMed Web of Science ®Google Scholar
• Chen MY, Huang DY, Wu A, et al. Efficacy of magnetic sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease in short term: A meta-analysis. Can J Gastroenterol Hepatol. 2017;7. DOI:10.1155/2017/9596342.
   Web of Science ®Google Scholar
• Du X, Wu JM, Hu ZW, et al. Laparoscopic Nissen (total) versus anterior 180 degrees fundoplication for gastro-esophageal reflux disease: A meta-analysis and systematic review. Medicine (Baltimore). 2017;96(37):e8085.
   PubMed Web of Science ®Google Scholar
• Loh Y, McGlone ER, Reddy M, et al. Is the LINX reflux management system an effective treatment for gastro-oesophageal reflux disease? Int J Surg. 2014;12(9):994–997.
   PubMed Web of Science ®Google Scholar
• Bell R, Lipham J, Louie B, et al. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: A randomized controlled trial. Gastrointest Endosc. 2018. DOI:10.1016/j.gie.2018.07.007.
   PubMed Web of Science ®Google Scholar